Minocycline is an old broad-spectrum tetracycline indicated for the treatment of various infections, including those due to minocycline-susceptible Acinetobacter spp. Susceptibility data worldwide are showing increasing rates of resistance of Acinetobacter baumannii to almost all antimicrobial classes, whereas minocycline seems to remain relatively potent against this significant pathogen. Since no new effective drugs have been released against MDR A. baumannii, minocycline is an attractive choice. Tracing back minocycline CLSI susceptibility breakpoints, it is evident that they have been based on old pharmacokinetic approaches. In an attempt to integrate the scarce new pharmacodynamic data, a Monte Carlo simulation was performed. It seems that the currently used breakpoints are, 8-fold elevated according to the approved dosage regimen, giving erroneously higher rates of minocycline susceptibility of A. baumannii. Therefore, current minocycline breakpoints merit re-evaluation in order to deliver reliable susceptibility profiles for selecting the appropriate therapy.
Introduction
Minocycline is a semi-synthetic derivative of the tetracycline family, exhibiting a better pharmacokinetic profile than older family members, with longer half-life and improved tissue penetration.
1,2 As a tetracycline, minocycline is a bacteriostatic antimicrobial agent that acts by inhibiting the binding of aminoacyl-tRNA to the ribosomal acceptor (A) site. 1 It was introduced in the 1970s and its intravenous formulation was withdrawn from the US market in 2005 but was brought back into production in 2009 1 as a last-resort drug for the treatment of infections due to MDR pathogens. The US FDA has issued clearance for both oral and intravenous minocycline formulations and provided an indication for treatment of infections due to Gram-negative bacteria, including Acinetobacter spp. 3 Infections due to MDR Acinetobacter baumannii are increasingly recognized worldwide and since new active antimicrobials have not been released, minocycline is one of the old drugs reconsidered as possibly effective treatment against MDR A. baumannii infections.
Interest has arisen in evaluating the clinical efficacy of minocycline against serious A. baumannii infections. Clinical studies have revealed overall encouraging clinical outcomes when minocycline is used either in combination with other agents or, in a few cases, as monotherapy against MDR A. baumannii pneumonia, bacteraemia, osteomyelitis, skin and soft tissue infection or wound infection. 4 Minocycline has for a long time been considered more active than tetracycline against Acinetobacter spp.
3 Epidemiological studies evaluating the activity of minocycline against MDR A. baumannii indicate susceptibility rates ranging between 56% and 94.3%, 2, 5 though considerably lower susceptibility rates of XDR and pandrug-resistant isolates have also been reported. 6 
What we already know
As tetracyclines represent an old class of antibiotics, the CLSI (formerly NCCLS) susceptibility breakpoints have a long history. In 1976, the CLSI assigned only tetracycline disc diffusion interpretive criteria of susceptibility (!19 mm) and resistance ( 14 mm), correlating to an MIC 4 mg/L for susceptibility and an MIC !16 mg/L for resistance. 3, 7, 8 Notably, recent observations have shown that in vitro susceptibility testing using tetracycline hydrochloride as a surrogate for the susceptibility of other tetracyclines underestimates minocycline susceptibility rates of A. baumannii strains. 3 Following a re-evaluation of CLSI disc diffusion breakpoints for tetracyclines against Enterobacteriaceae performed in 2007, 8 the disc diffusion criteria for minocycline were modified to susceptible !16 mm and resistant 12 mm for both Enterobacteriaceae and Acinetobacter spp. in CLSI M100-S17. 9 Overall, during recent decades the activities of all tetracyclines against A. baumannii have been interpreted using MIC breakpoints of MIC 4 mg/L for susceptibility and MIC !16 mg/L for resistance. On the other hand, EUCAST has not issued minocycline breakpoints for A. baumannii. It should be noted that, although officially there are no clinical breakpoints for tigecycline (a minocycline-derived agent) against A. baumannii given by either CLSI or EUCAST, tigecycline clinical FDA breakpoints for Enterobacteriaceae are commonly applied, which are much lower (MIC 2 mg/L for susceptibility and MIC !8 mg/L for resistance). This may partly account for the higher minocycline susceptibility rates documented in the literature. 10 Currently, setting breakpoints for an antimicrobial agent against a pathogen is a very complex task, since numerous factors should be taken into account, including standard dosing, MIC distributions of the organisms of interest, pharmacokinetic and pharmacodynamic parameters, modelling data and clinical data relating outcome to MIC values. 11, 12 Tetracyclines were released before pharmacodynamics were acknowledged as an important factor in dosing regimens and in setting breakpoints. Therefore, dosing regimens (usually 100 mg every 12 h) are based only on pharmacokinetics and the long-term experience of minocycline usage rather than pharmacodynamic data. Besides, all breakpoints were based on pharmacokinetic factors mostly published before the 1980s. 13 New findings and one step further Pharmacokinetic/pharmacodynamic studies on minocycline are scarce. Bowker et al.
14 performed a pharmacokinetic/pharmacodynamic study using a hollow-fibre in vitro model to simulate freedrug serum concentrations of oral minocycline (100 mg/12 h) against MRSA strains, confirming that minocycline is an AUC/MICdriven agent. The AUC/MIC ratio has already been used to develop minocycline susceptibility breakpoints for Neisseria meningitidis, 15 but also for doxycycline MIC breakpoints and revision of tetracycline breakpoints for Streptococcus pneumoniae. 16 The proportion of minocycline protein binding is considered to be 76%, 17 and therefore the free AUC/MIC (fAUC/MIC) would be of interest, since only the free fraction is capable of reaching the extravascular anatomical compartments and exhibiting an antimicrobial effect. It has recently been estimated that a pharmacodynamic target (PDT) of fAUC/MIC equal to 20-25 is required for A. baumannii and the fAUC for a 200 mg dose of minocycline should be 18-40 mgÁh/L. 17 Therefore, by taking the mean value of the PDT index and rearranging the formula PDT " fAUC/MIC to solve for MIC, the MIC breakpoint is 18-40/22.5"1-2 mg/L to the nearest 2-fold MIC values for the lower and upper values of fAUC, respectively.
The presented values, though, represent just a population mean and not the entire distribution within a population. Thus, in order to have a first estimate of the minocycline breakpoint for A. baumannii, the distribution of AUC 0-1 from published data was used. 18 A Monte Carlo simulation was carried out with 10000 generated AUC values from a log-normal distribution obtained from the 16 AUC values, 18 for a daily dose of 200 mg. This was repeated for daily doses of 100 and 400 mg by halving and doubling, respectively, the AUC values. The PTA values for the various MICs are shown in Figure 1 , which indicates that, for a 200 mg daily dose, the proportion of patients achieving an fAUC/MIC ratio above 25 drops rapidly for MICs .0.5 mg/L. As expected, halving or doubling the dose results in shifting the curve one position to the left or right, respectively; i.e. the breakpoint for 100 mg/day is 0.25 mg/L and for 400 mg/day it is 1 mg/L. This MIC breakpoint, although calculated roughly, is much lower, probably reaching an 8-fold reduction, than the one used for decades. The existing breakpoint MIC of 4 mg/L for susceptibility may be more relevant when higher doses are used. Actually, there is favourable published experience with the dosing regimen of 400 mg/day used for A. baumannii infections. 4 Notably, even more elevated doses have been reported in the literature in noninfectious diseases. Maximum loading doses of 800 mg/day used in acute spinal cord injury 19 and 700 mg/day in stroke patients 17 have been published. The estimation of minocycline MIC breakpoints according to the dose regimen, though, is even more complex, since tetracyclines, including minocycline, exhibit an atypical non-linear protein binding pattern, meaning that the free fraction of minocycline decreases with increasing total minocycline concentration. 20 This might be translated into an unpredictable MIC breakpoint in relation to the dosage elevation. These new data may suggest that the activity of minocycline against A. baumannii may not be that high when the indicated doses are used or that maybe higher doses would justify the current breakpoints.
Conclusions
Minocycline is an attractive alternative for treating infections due to MDR A. baumannii strains that retain susceptibility to minocycline. Published literature focuses on the need for further clinical evidence on minocycline usage as a last-resort drug. Apart from that, we would like to draw attention to the reliability of laboratory minocycline susceptibility evaluation, which is still based on the existing interpretive criteria, established with old techniques, and may need re-evaluation. However, a reassessment of the MIC clinical breakpoints for A. baumannii has not been performed during recent decades. A possible explanation may be that it may need investment of resources that the concerned parties may not be willing to make, in order to provide clinical data. 12 Nevertheless, EUCAST suggests that when a new agent in an existing class of antimicrobial agents is introduced (i.e. tigecycline in the class of tetracyclines), breakpoints of older agents, such as minocycline, probably determined with older techniques, merit revision, in order to prevent unequal estimated usefulness of the agents in the class. 21 It is also worth mentioning that MIC distributions, not available in the 1980s, are now released on the EUCAST website. Our first estimate indicates that the MIC susceptibility breakpoint may actually be 8-fold lower than the one currently used. Review of dosing regimens and consideration of MIC distributions, pharmacokinetic/pharmacodynamic studies and the impact of the tet(B) resistance determinant will reveal new data in order to proceed to an update of clinical breakpoints. This re-evaluation will confirm that minocycline susceptibility is not erroneously estimated by in vitro susceptibility testing. For debate
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